Todd M Morgan

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, 1959 NE Pacific, BB 1115, Box 356510, Seattle, WA 98195, USA
    Clin Cancer Res 15:677-83. 2009
  2. pmc Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients
    Ilona N Holcomb
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Res 68:5599-608. 2008
  3. ncbi request reprint Complications of scrotal surgery for benign conditions
    Mia A Swartz
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Urology 69:616-9. 2007
  4. pmc Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Curr Cancer Drug Targets 9:237-49. 2009
  5. ncbi request reprint Detection and characterization of circulating and disseminated prostate cancer cells
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Front Biosci 12:3000-9. 2007
  6. pmc RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Prostate 68:861-71. 2008
  7. doi request reprint Primary scrotal cancer: disease characteristics and increasing incidence
    Jonathan L Wright
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Urology 72:1139-43. 2008

Collaborators

Detail Information

Publications7

  1. pmc Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, 1959 NE Pacific, BB 1115, Box 356510, Seattle, WA 98195, USA
    Clin Cancer Res 15:677-83. 2009
    ..We sought to determine if epithelial-like cells identified from bone marrow in patients after radical prostatectomy, commonly called disseminated tumor cells (DTC), were associated with biochemical recurrence...
  2. pmc Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients
    Ilona N Holcomb
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Res 68:5599-608. 2008
    ..Our analysis lays the foundation for elucidation of the relationship between DTC genomic alterations and progressive prostate cancer...
  3. ncbi request reprint Complications of scrotal surgery for benign conditions
    Mia A Swartz
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Urology 69:616-9. 2007
    ..Frequent complications have been reported after scrotal surgery. We reviewed our experience to determine the complication rates, risk factors, and how our experience might differ from other series...
  4. pmc Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Curr Cancer Drug Targets 9:237-49. 2009
    ..In this article we review the data surrounding PI3K/Akt/mTOR inhibition in prostate cancer and their clinical implications...
  5. ncbi request reprint Detection and characterization of circulating and disseminated prostate cancer cells
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Front Biosci 12:3000-9. 2007
    ..Additionally, we discuss the isolation and analysis of disseminated cells and examine their potential value in helping to understand the relationship between these cells and tumor metastasis...
  6. pmc RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
    Todd M Morgan
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Prostate 68:861-71. 2008
    ..RAD001 (Everolimus) is a new orally available mTOR inhibitor. The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in combination with docetaxel and zoledronic acid...
  7. doi request reprint Primary scrotal cancer: disease characteristics and increasing incidence
    Jonathan L Wright
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Urology 72:1139-43. 2008
    ..Using a population-based cancer registry, we describe the demographic and pathologic characteristics of scrotal cancer and report the incidence trends over time...